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Abstract
Poly(ADP-ribose) polymerase 1 (PARP1) is a chromatin-associated nuclear protein and functions as a
molecular stress sensor. At the cellular level, PARP1 has been implicated in a wide range of processes,
such as maintenance of genome stability, cell death, and transcription. PARP1 functions as a
transcriptional coactivator of nuclear factor B (NF-B) and hypoxia inducible factor 1 (HIF1). In
proteomic studies, PARP1 was found to be modified by small ubiquitin-like modifiers (SUMOs). Here,
we characterize PARP1 as a substrate for modification by SUMO1 and SUMO3, both in vitro and in
vivo. PARP1 is sumoylated at the single lysine residue K486 within its automodification domain.
Interestingly, modification of PARP1 with SUMO does not affect its ADP-ribosylation activity but
completely abrogates p300-mediated acetylation of PARP1, revealing an intriguing crosstalk of
sumoylation and acetylation on PARP1. Genetic complementation of PARP1-depleted cells with
wildtype and sumoylation-deficient PARP1 revealed that SUMO modification of PARP1 restrains its
transcriptional coactivator function and subsequently reduces gene expression of distinct
PARP1-regulated target genes. Messner, S., Schuermann, D., Altmeyer, M., Kassner, I., Schmidt, D.,
Scha¨r, P., Mu¨ller, S., and Hottiger, M. O. Sumoylation of poly(ADP-ribose) polymerase 1 inhibits its
acetylation and restrains transcriptional coactivator function.
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ABSTRACT Poly(ADP-ribose) polymerase 1 (PARP1)
is a chromatin-associated nuclear protein and functions
as a molecular stress sensor. At the cellular level,
PARP1 has been implicated in a wide range of pro-
cesses, such as maintenance of genome stability, cell
death, and transcription. PARP1 functions as a tran-
scriptional coactivator of nuclear factor B (NF-B)
and hypoxia inducible factor 1 (HIF1). In proteomic
studies, PARP1 was found to be modified by small
ubiquitin-like modifiers (SUMOs). Here, we character-
ize PARP1 as a substrate for modification by SUMO1
and SUMO3, both in vitro and in vivo. PARP1 is
sumoylated at the single lysine residue K486 within its
automodification domain. Interestingly, modification
of PARP1 with SUMO does not affect its ADP-ribosy-
lation activity but completely abrogates p300-mediated
acetylation of PARP1, revealing an intriguing crosstalk
of sumoylation and acetylation on PARP1. Genetic
complementation of PARP1-depleted cells with wild-
type and sumoylation-deficient PARP1 revealed that
SUMO modification of PARP1 restrains its transcrip-
tional coactivator function and subsequently reduces
gene expression of distinct PARP1-regulated target
genes. Messner, S., Schuermann, D., Altmeyer, M.,
Kassner, I., Schmidt, D., Scha¨r, P., Mu¨ller, S., and
Hottiger, M. O. Sumoylation of poly(ADP-ribose) poly-
merase 1 inhibits its acetylation and restrains transcrip-
tional coactivator function. FASEB J. 23, 3978–3989
(2009). www.fasebj.org
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Poly(ADP-ribose) polymerase 1 (PARP1) is an abun-
dant nuclear chromatin-associated multifunctional en-
zyme found in higher eukaryotes that belongs to a
family of 5 “bona fide” PARP enzymes (1). PARP1 has an
amino-terminal DNA-binding domain (DBD) contain-
ing 3 zinc finger motifs, as well as a central automodi-
fication domain (AMD), which functions as a target of
direct covalent automodification. The carboxyl-termi-
nal catalytic domain polymerizes linear or branched
chains of ADP-ribose from the donor nicotinamide
adenine dinucleotide (NAD). ADP-ribose is mainly
attached on PARP1, but also other proteins are modi-
fied (2). Together, the DBD and the automodification
domain allow PARP1 to interact with genomic DNA
and chromatin. Although originally characterized as a
key factor in DNA single strand-break repair, a wealth
of studies over the past decade have demonstrated a
role of PARP1 in the regulation of gene expression
under basal, signal-activated, and stress-activated condi-
tions (1, 3). Recent studies have highlighted the role of
PARP1 in distinct modes of transcriptional regulation
and provided novel insight into the cellular signaling
systems that interface with PARP1 in the nucleus (4).
The basal enzymatic activity of PARP1 is very low, but
it is stimulated dramatically under conditions of cellu-
lar stress (2, 3). Activation of PARP1 results in the
synthesis of poly(ADP-ribose) (PAR) from NAD and
the release of nicotinamide as a reaction by-product
(1). Following PARP1 activation, intracellular PAR lev-
els can rise 10- to 500-fold (1), caused by a mechanism
that remains to be resolved. Very recently, we identified
3 lysine residues in the automodification domain of
PARP1 as acceptor sites for auto-ADP-ribosylation (5).
PARP1 is the main acceptor for poly(ADP-ribosyl)ation
in vivo, and automodification of PARP1 abolishes its
affinity for NAD and DNA (5). Remarkably, the same
3 ribosylated lysines (K498, K521, K524) were previ-
ously identified as targets for acetylation by the histone
acetyltransferase p300 (6). Acetylation of PARP1 has
been reported to be important for its transactivation
activity (6). Recently, we also highlighted the role of
PARP1 as a transcriptional coactivator of hypoxia in-
ducible factor 1- (HIF1-). On hypoxic induction of
cells, PARP1 was shown to interact with HIF1- and to
regulate the transcriptional activity of HIF1--depen-
dent genes (7).
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Another post-translational protein modification in
response to cellular stresses is the conjugation of small
ubiquitin-like modifiers (SUMOs) (8). SUMOs regulate
diverse cellular processes, including cell-cycle progres-
sion, genome stability, intracellular trafficking, and
transcription (9, 10). In many cases, SUMO conjuga-
tion alters localization and/or activity of the substrate
by providing a new protein-protein interaction inter-
face. However, in certain cases, SUMO modification
can also prevent distinct protein-protein interactions.
Mammalian cells express three SUMO paralogs:
SUMO2 and SUMO3, which are 96% identical and only
differ by three N-terminal residues, and SUMO1, which
is 45% identical to SUMO2/3. Moreover, SUMO2/3
proteins are able to form chains, which SUMO1 cannot
(11). Although virtually all of the SUMO1 is engaged in
conjugates, there is a free pool of the more abundant
SUMO2/3 that is utilized when cells are stressed by
heat shock or ethanol exposure (12). It is clear that
proteins can be modified selectively by SUMO1 and
SUMO2/3. Growing evidence suggests that SUMO2/3
and SUMO1 have some unique biological functions
(12–14).
SUMO family proteins are conjugated to target ly-
sines via a cascade of the E1-activating enzyme (SAE1/
SAE2), the E2-conjugating enzyme Ubc9, and E3
SUMO ligases (8, 10). The SUMO E2 protein Ubc9
often recognizes the consensus sequence KxE/D
(where  is a large hydrophobic amino acid, such as
isoleucine or valine, and x is any amino acid) in the
target protein and catalyzes SUMO conjugation (8).
Generally, sumoylation with SAE1/SAE2 and Ubc9 only
is rather inefficient, and additional proteins known as
SUMO E3 ligases are often required to accelerate this
reaction (10). A family of deconjugation enzymes,
SENPs, is responsible for the removal of SUMO from
target lysines (15), which accounts for the transient
nature of this modification. In human cells, six mem-
bers of this family (SENP1-3 and SENP5-7) have been
identified. Importantly distinct members exhibit para-
log specificity and show a characteristic subcellular
localization, indicating that spatial control is an impor-
tant regulatory concept of SENP activity.
Several proteomic studies to identify substrates for
SUMO conjugation have been reported (16–18). In
this context, PARP1 was detected to be sumoylated in
HEK293 cells and in K562 cells. SUMO modification of
proteins that regulate transcription has been associated
with dynamic regulation of gene expression (9, 19). A
large number of transcriptional regulators, including
transcription factors, cofactors, and chromatin-modify-
ing enzymes, have been found to be substrates of
SUMO modification. Generally, a SUMO-modified fac-
tor exists in a dynamic distribution between the SUMO-
modified and unmodified forms, and although the
SUMO-modified form of a protein is often difficult to
detect, it can have a great impact on transcriptional
activation (9, 10). Sumoylation of transcription factors
has generally been correlated with transcriptional re-
pression (9, 10). The specific effects, however, have to
be determined experimentally for each case.
In this study, we characterize the modification of
PARP1 through SUMO1 and SUMO3. The modifica-
tion primarily occurs at a lysine residue within the
automodification domain of PARP1. The attachment
site is close to hotspots of other post-translational
modifications of PARP1, such as ADP-ribosylation and
acetylation. This proximity led us to investigate a po-
tential crosstalk of these modifications. Sumoylation of
PARP1 inhibits its acetylation through p300, and cor-
respondingly, a sumoylation-deficient PARP1 mutant
has a higher acetylation status than wild-type PARP1. In
addition, a PARP1 sumoylation-deficient cell line exhib-
its increased transcriptional activity of genes under the
control of transcription factor HIF1-.
MATERIALS AND METHODS
Chemicals and antibodies
Protein G sepharose and glutathione sepharose 4B were
purchased from GE Healthcare (Les Ulis, France), 32P-NAD
and 35S-methionine were from PerkinElmer (Boston, MA,
USA). NAD, trichostatin A (TSA), acetyl-coenzyme A, 3AB,
ATP, anti-tubulin, and anti-Flag (M2) were obtained from
Sigma-Aldrich (Milan, Italy). Anti-p300 (C20) was obtained
from Santa Cruz Biotechnology (Santa Cruz, CA, USA) and
anti-HA antibody 16B12 from Covance (Evansville, IL, USA).
Anti-myc antibody (9E10) was purchased from Roche (Basel,
Switzerland), SUMO2/3 (18H8) was obtained from Cell
Signaling (Beverly, MA, USA), and His antibody was from
Qiagen (Valencia, Spain). Monoclonal CAIX antibody super-
natant from hybridoma was a gift from D. Stiehl (University of
Zurich, Zurich, Switzerland). Anti-PARP1 was produced in
this laboratory; anti-acetyl-PARP1 was generated in collabora-
tion with the monoclonal antibody core facility at the EMBL
Monterotondo (Monterotondo, Italy).
Cell culture and transfection
HEK293T and K562 cells were grown under standard condi-
tions. Transfections were carried out with the calcium phos-
phate method. Whole-cell extracts were prepared as de-
scribed previously (20) with 10 mM NEM and/or HDAC
inhibitors (2 M TSA, 5 mM NAM, 1 mM Na-butyrate).
Nuclear extracts were prepared as described previously (6).
Plasmids
The baculovirus expression vectors pQE-TriSystem (Qiagen)
and BacPak8 (Clontech, Mountain View, CA, USA) were used
for the expression of recombinant proteins in Sf21 insect
cells, as described previously (21). pcDNA-myc-SUMO1, myc-
SUMO3, and myc-Ubc9 expression plasmids were kindly
provided by R. T. Hay (University of Dundee, Dundee, UK).
PARP1 was cloned into a pCMV-HA vector with NheI/NotI
restriction enzymes. pCU vector with Ubc9 was a kind gift
from R. Niedenthal (Hannover Medical School, Hannover,
Germany). PARP1 was cloned into pCU with NheI/SmaI
restriction enzymes, generating a 15-aa linker between PARP1
and Ubc9. pCMV-Flag-p300 was used for expression in mam-
malian cells. Plasmids for SUMO proteases SENP1-6 were in
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pCI-Flag backbone. Short hairpin RNA was cloned and ex-
pressed in pSUPER vector.
Cloning, expression, and purification of recombinant
proteins
Wild-type hPARP1 (National Center for Biotechnology Infor-
mation ID: BC037545) was cloned and expressed as amino-
terminal HA-tagged and carboxyl-terminal His-tagged pro-
tein. HA-PARP1, HA-PARP1 K486R, p300, SUMO1, SUMO3,
and Ubc9 proteins were purified by 1-step affinity chromatog-
raphy using ProBond resin, according to the manufacturer‘s
recommendations (Invitrogen, Carlsbad, CA, USA). GST-
SUMO3, SUMO3, SENP2 (aa 364-569), and SENP2 (aa
364-569 C548S) were cloned in pGEX-vectors, expressed
and purified with glutathione sepharose, according to the
manufacturer‘s recommendations (GE Healthcare). The
double-tagged heterodimeric human E1-activating enzyme
was expressed from the pGEX-E1H6 vector and purified by
sequential GST beads and nickel beads; GST-cleavage was
performed through thrombin, and the recombinant pro-
tein was loaded and eluted from nickel beads using stan-
dard protocols.
In vitro sumoylation assay
The reaction was carried out in standard SUMO reaction
buffer (50 mM Tris-HCl, pH 8.0; 50 mM NaCl; 5 mM MgCl2;
10% glycerol; and 0.5 mM DTT). 5 mM ATP was added to
start the reaction. Incubation time was 30 min at 30°C, unless
otherwise indicated. The final concentration of proteins was
100 nM for SAE1/SAE2, 500 nM Ubc9, 5 M SUMO1/
SUMO3, and 500 nM HA-PARP1.
Purification of sumoylated PARP1
The sumoylation reaction was 15 scaled up, and the incu-
bation time was increased to 120 min at 30°C. Instead of
SUMO3, a GST-tagged SUMO3 at a final concentration of 10
M was used. After sumoylation, the sample was diluted with
2 the volume with SUMO-purification buffer (50 mM
Tris-HCl, pH 7.5; 150 mM NaCl; 1 mM EDTA; and 1 mM
DTT) and bound to glutathione sepharose beads. After 60
min of incubation on rolls at 4°C, the supernatant was washed
away with the same buffer, and 2 U of PreScission protease
was added to the beads and incubated 16 h at 4°C. The
supernatant was used for experiments with sumoylated
PARP1.
Desumoylation of PARP1 in vitro
Purified sumoylated PARP1 was subjected to active recombi-
nant SENP2 (aa 364-569) or inactive SENP2 (aa 364-569
C548S) treatment in SUMO-purification buffer (50 mM Tris-
HCl, pH 7.5; 150 mM NaCl; 1 mM EDTA; and 1 mM DTT) for
15 min at 30°C with a concentration of 10 ng SENP2/l.
32P-NAD automodification
Sumoylated or desumoylated PARP1 in SUMO-purification
buffer (50 mM Tris-HCl, pH 7.5; 150 mM NaCl; 1 mM EDTA;
and 1 mM DTT) was supplemented with 4 mM MgCl2 and 5
pmol of annealed double-stranded oligomer (5-GGAATTCC-
3). The reaction was started by adding 32P-NAD at a final
concentration of 100 nM NAD. Automodification was al-
lowed for 5 min at 30°C. Reactions were stopped by the
addition of SDS-PAGE-loading buffer and boiling for 5 min at
95°C. Samples were subjected to SDS-PAGE, followed by
detection of automodification by autoradiography.
PAR detection by silver staining
Following synthesis of PAR in the presence of 400 M NAD
and 5 pmol EcoRI-linker DNA for 20 min, PAR chains were
purified and separated by modified DNA-sequencing gel
electrophoresis, as described previously (22).
Immunoprecipitation and nickel-NTA pulldown
Sumoylated or desumoylated PARP1 was bound to protein G
sepharose beads with anti-HA antibody in SUMO-purification
buffer. The beads were washed and adjusted to IP buffer (50
mM Tris-HCL, pH 8.0; 100 mM NaCl; 0.25% Nonidet P-40;
and 1 g/ml protease inhibitors). Recombinant p300 (2 g)
was added to the beads and incubated for 2 h at 4°C on rolls.
Washing of the beads with the same buffer removed unbound
p300. Immunoprecipitation of nuclear extracts was done with
HA antibody with IP-binding buffer (20 mM HEPES, 150 mM
NaCl, and 0.25% Nonidet P-40; 1 g/ml), protease inhibitors,
and HDAC inhibitors (2 M TSA, 5 mM NAM, 1 mM
Na-butyrate). The salt concentration was increased with 50
mM KCl for washing steps. Elution of bound proteins was
done with SDS-PAGE loading buffer and boiled for 5 min
at 95°C. Nickel-NTA pulldown was done as described
previously (23).
HAT Assay
Sumoylated or desumoylated PARP1 was subjected to in vitro
acetylation assay with recombinant p300 as described else-
where (24).
Knockdown and complementation of PARP1 in K562 cells
Generation of viruses and transduction of cells was done as
described earlier (25). shRNA was cloned into pRDI vector
and transduced to K562 cells. The short hairpin RNA was
designed against 5UTR region of PARP1 mRNA. Transduced
cells were selected through puromycine resistance gene.
Complementation of cells was done with pRRL-myc-PARP1
vectors containing a blasticidine resistance marker and sub-
sequently selected with this antibiotic.
RNA preparation
Total RNA was isolated from 3 biological replicates of com-
plemented K562 cells with the Total RNA Isolation kit (Agi-
lent Technologies, Santa Clara, CA, USA). Reverse transcrip-
tion was achieved with the High-Capacity cDNA Reverse
Transcription kit (Applied Biosystems, Foster City, CA, USA).
Quantitative PCR
Total reverse-transcribed cDNA from untreated or treated
K562 cells was used for q-PCR with primers against carbonic
anhydrase IX, LOXL2, and Pdk1. Amplification products
were analyzed by SYBR Green (Quantace, London, UK), and
ribosomal protein L28 was used to normalize for differences
in RNA input. Rotor-Gene3000A (Qiagen, Basel, Switzerland)
was used to perform the real-time PCR reactions.
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RESULTS
PARP1 is sumoylated in vivo
Because PARP1 was identified as a SUMO modification
target in proteomic studies, we aimed to confirm that
PARP1 is indeed sumoylated in vivo. HA-tagged PARP1
was coexpressed with myc-tagged SUMO1 or SUMO3 in
HEK293T cells, and extracts were analyzed by Western
blot. Ectopic expression of SUMO1 or SUMO3 per se
induced the modification of a multitude of proteins
(Fig. 1A, bottom). Expression of SUMO induced a
higher molecular form of PARP1 (depicted as Su-
PARP1), which was more prominent in the presence of
SUMO3 as compared to SUMO1, suggesting that
PARP1 is preferentially conjugated with SUMO3 (Fig.
1A). Expressing His-tagged SUMO, we could enrich an
anti-PARP1-reactive species on Ni-NTA beads, thus val-
idating that the higher molecular form corresponds,
indeed, to a covalent SUMO-PARP1 conjugate (Fig.
1B). Only one distinctive band of sumoylated PARP1
was detected, suggesting that PARP1 is monosumoy-
lated at a single lysine residue under the tested condi-
tions. Similar results were obtained when PARP1 was
expressed as fusion protein with Ubc9/E2 conjugation
protein, although the overall modification rate was
clearly enhanced (Supplemental Fig. 1A). Mutation of
the catalytic cysteine of the fused Ubc9 resulted in a
strong reduction of the modification, indicating that
the Ubc9 fused to PARP1 catalyzes the sumoylation of
PARP1 (Supplemental Fig. 1B). Immunoprecipitation
of this fusion protein in extracts of cells expressing
myc-tagged SUMO3 and subsequent Western blot anal-
ysis using an anti-myc antibody revealed SUMO moi-
eties on PARP1, providing additional evidence for
covalent modification of PARP1 with SUMO (Supple-
mental Fig. 1C). To test whether PARP1 would bind to
SUMO noncovalently via a SUMO-interacting motif
(SIM), GST pulldowns were performed with conjuga-
tion-deficient SUMO1-4 and RelA/p65 as a positive
control (Supplemental Fig. 2A–C). Although PARP1
was able to interact with RelA/p65, no interaction was
detectable with GST or all tested SUMOs. Thus, we
conclude that PARP1 is covalently modified by SUMO.
SENP1 and SENP3 are able to desumoylate PARP1
SUMO proteases are known to reverse sumoylation of
proteins. To test whether SUMO proteases act on
Figure 1. PARP1 is sumoylated in vivo. A) HA-PARP1,
myc-SUMO1, or myc-SUMO3 expression plasmids were
transfected in HEK293T. Whole-cell extracts were taken
in presence of 10 mM NEM and resolved on SDS-PAGE
and subsequently analyzed through Western blotting
with the indicated antibodies. Sumoylated PARP1 is
indicated as Su-PARP1. B) Denaturating nickel pulldown
of whole-cell extracts from transfected HEK293T cells.
Cells were transfected with SUMO2 alone or with
His-tagged SUMO2. Detection of sumoylated PARP1
was performed with anti-PARP1 antibody. C) HEK293T
cells were transfected with a mix of HA-PARP1, His-
SUMO3, and myc-Ubc9 expression plasmids and the indi-
cated plasmids for expression of SUMO proteases SENP1
and SENP3, or the catalytically inactive mutant counter-
part, respectively. Expression levels of the SENPs were
monitored with anti-Flag antibody.D) HEK293T cells were cotransfected with flag-tagged expression plasmids for SENP1 or SENP3
and pSUPER vector with shRNAs against SENPs. Knockdown efficiency after 28-h expression was examined with
anti-Flag antibody. E) Knockdown of SENP1 and SENP3 was achieved as in D, but in addition, a mix of HA-PARP1,
His-SUMO3, and myc-Ubc9 was cotransfected in HEK293T cells. Cell extracts were prepared and examined with the
anti-PARP1 and anti-His antibodies.
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SUMO-modified PARP1, we coexpressed wild-type or
catalytically inactive SENP1 and SENP3 with PARP1 and
SUMO3 in HEK293T cells (Fig. 1C). This showed that
coexpression of catalytically active SENP1 and SENP3
deconjugated SUMO3 from PARP1 (Fig. 1C). Corre-
spondingly, knockdown of SENP1 and SENP3 with
transiently transfected shRNAs (Fig. 1D) resulted in the
accumulation of sumoylated PARP1, as compared to
the control (Fig. 1E), indicating that SENP1 and SENP3
can act on PARP1-SUMO conjugates at physiological
expression levels. Taken together, our results illustrate
that PARP1 is preferably modified by SUMO3 and
desumoylated by the isopeptidases SENP1 and SENP3.
Furthermore, sumoylation of PARP1 seems thus to be a
transient and reversible modification.
PARP1 is sumoylated at K486 in vitro and in vivo
The consensus sumoylation site sequence is KxE/D
(8). As determined by the SUMOsp analysis program
(http://sumosp.biocuckoo.org), the highest score
matched to lysine 486 in human PARP1 (Fig. 2A),
which is located in proximity to previously described
sites of acetylation and ADP ribosylation. To confirm
PARP1 sumoylation in vitro and to map the modifica-
tion site, we established an in vitro sumoylation system
reconstituted with recombinant human E1 (SAE1/
SAE2 heterodimer), E2 (Ubc9), wild-type SUMO1, or
SUMO3 and wild-type PARP1 (Fig. 2B). PARP1 sumoy-
lation was efficiently reconstituted in vitro with purified
proteins: reactions containing all components pro-
duced slower migrating PARP1 forms, consistent with
conjugated SUMO moieties. Attachment of a single
moiety was detected with low E2 concentrations (run-
ning at 140 kDa), whereas multiple SUMO moieties
were attached only at higher E2 concentrations (Fig.
2B). One additional band between 120 and 140 kDa was
observed at elevated Ubc9 concentrations and likely rep-
resents the modification of a degradation product of
PARP1 by SUMO3. To test for putative sumoylation sites
in PARP1, lysine 486 of PARP1 was substituted with
arginine (PARP1 K486R) and analyzed in vitro. Substitu-
tion did completely prevent the sumoylation of PARP1 in
vitro with SUMO1, SUMO3, or GST-tagged SUMO3, as
monitored by Western blot analysis (Fig. 2C, D), indicat-
ing that K486 is the major SUMO acceptor site of PARP1.
Figure 2. PARP1 is sumoylated at K486 in vitro and in vivo. A) Schematic
overview of human PARP1 domains. Putative sumoylation consensus
motif around lysine 486 is highlighted. Reported post-translational
modifications are shown in bold. ac, acetylation; ADPR, ADP-ribosyla-
tion. B) In vitro sumoylation assay with recombinant ATP-dependent
SUMO E1 (SAE1, SAE2)-activating enzyme, SUMO E2-conjugating
enzyme Ubc9, and SUMO3. Sumoylation reaction was carried out under
standard assay conditions for 30 min. PARP1 was detected with anti-
PARP1 antibody. C) In vitro sumoylation with purified HA-PARP1
wild-type or HA-PARP1 K486R as in B for the indicated time. D) In vitro
sumoylation assay with GST-tagged SUMO3 or with SUMO1, either with
HA-PARP1 wild-type or HA-PARP1 K486R for the indicated incubation
time. E) HEK293T cells were transfected with expression plasmids for HA-PARP1, HA-PARP1 K486R, or myc-SUMO3,
respectively. Whole-cell extracts were analyzed with anti-HA antibody and anti-myc antibody. Saturated levels of unbound
myc-SUMO3 were detected in the control Western blot.
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To verify sumoylation of PARP1 at K486 in vivo, we
coexpressed wild-type or the K486R mutant of PARP1
with myc-tagged SUMO3. Sumoylation of wild-type
PARP1 could be detected but not of the K486R mutant
(Fig. 2E), confirming K486 as the main sumoylated
residue in vivo.
Sumoylation of PARP1 does not affect its ADP
ribosylation activity
To explore a potential interplay of PARP1 sumoylation
with PARP1 function, we modified the established in
vitro sumoylation system to purify sumoylated PARP1. A
large-scale sumoylation reaction was performed with
GST-tagged SUMO3, E1–E2 enzymes, and HA-PARP1,
followed by GST affinity purification and subsequent
protease digestion to remove the GST tag and to purify
Su-PARP1, specifically modified at K486 (Fig. 3A). On
purification, only Su-PARP1 could be detected, indi-
cating that no unmodified PARP1 was in the purified
complex (Fig. 3B). Because PARP1 was described to
form a homodimer, this result suggests that both
subunits are equally accessible for SUMO-conjuga-
tion. PARP1 was also efficiently sumoylated in the
presence of double-stranded DNA ends, suggesting
that binding of PARP1 to DNA does not affect its
sumoylation in vitro (Supplemental Fig. 3A). Simi-
larly, Su-PARP1 was still able to bind specifically to
DNA fragments that mimic damaged DNA (Supple-
mental Fig. 3B).
To determine whether sumoylation regulates the
intrinsic ADP-ribosylation activity of PARP1, mono-
ADP-ribosylation of purified Su-PARP1 was measured
using an in vitro ADP-ribosylation assay in the presence
of 100 nM 32P-NAD. Sumoylation of PARP1 still allows
its mono-ADP-ribosylation activity (Fig. 3B, lane 1). To
compare the extent of ADP ribosylation, Su-PARP1 was
either desumoylated by recombinant SENP2 (aa 364-
569) before or after ADP ribosylation took place (Fig.
3B, lanes 2 and 3). Quantification of the detected
radioactivity confirmed that both proteins were modi-
fied to the same extent. Similar experiments were
repeated with 400 M NAD, a concentration that
allows detection of poly(ADP-ribosyl)ation of PARP1.
PAR polymers synthesized by Su-PARP1 and desumoy-
lated PARP1 were isolated and analyzed with silver-
stained PAGE (Fig. 3C). Neither the amount nor the
distribution of freshly synthesized PAR was altered by
sumoylated PARP1, indicating that SUMO modification
neither alters the ability of PARP1 to initiate nor to
extend PAR synthesis. In addition, overexpression of
SUMO3 in HEK293T cells per se did not stimulate PAR
formation (Supplemental Fig. 4A), although PARP1 is
sumoylated under these conditions (see Fig. 1A, last
lane). Furthermore, H2O2-treated cells showed PAR
formation (Supplemental Fig. 4B), which was indepen-
dent of SUMO3 levels, indicating that SUMO modifi-
cation of PARP1 does not enhance its poly(ADP-ribo-
syl)ation activity. To test the possibility of differential
localization of PARP1 upon sumoylation, we overex-
Figure 3. Sumoylation of PARP1 does
not affect its ADP-ribosylation activity.
A) Purification of sumoylated PARP1.
Purified HA-PARP1 from insect cells
was sumoylated in vitro with GST-
SUMO3 (a), which occurred site-spe-
cific on lysine 486. GST-SUMO3-con-
jugated PARP1 was captured on
glutathione sepharose beads (b). GST
tag was removed using a GST-tagged
PreScission protease (c), which was added to the beads. Supernatant consisted of sumoylated PARP1, which was either
incubated with active recombinant SENP2 fragment (aa 364-569) or the inactive mutant SENP2 C548S. B) Sumoylated
PARP1 (lanes 1 and 2) or desumoylated PARP1 (lane 3) was incubated with 100 nM radiolabeled 32P-NAD and 5 pmol
EcoRI-linker DNA. Reaction was stopped with PARP-inhibitor 3AB, and active SENP2 was added to deconjugate SUMO3
from PARP1 (lane 2), thus generating free PARP1. Mono(ADP-ribosyl)ation was monitored with autoradiography.
C) Silver stain of isolated PAR generated by sumoylated PARP1 (lanes 1 and 3) or by desumoylated PARP1 (lanes 2 and
4). Reaction was carried out in the absence (lanes 1 and 2) or in the presence (lanes 3 and 4) of EcoRI-linker DNA at 400
M NAD. D) Mono(ADP-ribosyl)ation of PARP1 in the presence or absence of PARP-inhibitor 3AB with 100 nM NAD.
Each sample was supplemented with E1, E2, and SUMO3 proteins. Reaction was stopped after a 5-min incubation time
with 3AB (lanes 3 and 4), and ATP was added (lanes 2 and 4). After the sumoylation reaction, proteins were separated
by SDS-PAGE and analyzed by autoradiography.
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pressed SUMO3 in cells and monitored PARP1 local-
ization by immunofluorescence. However, we did not
observe differential localization of PARP1 within the
nucleus upon ectopic SUMO3 expression (Supplemen-
tal Fig. 4C).
We recently reported that PARP1 is auto-ADP-
ribosylated at several lysines adjacent to the identi-
fied sumoylation site (26). To exclude that ADP-
ribosylation would affect sumoylation, we mono-ADP-
ribosylated PARP1 in vitro with radioactive NAD and
subsequently sumoylated the labeled PARP1 fraction
(Fig. 3D). PARP1 was sumoylated in an ATP-depen-
dent manner independent of its ADP-ribosylation.
Consistently, in vivo treatment of cells with the PARP
inhibitor 3-amino-benzamide (3AB) did not affect
sumoylation (data not shown). Taken together, this
suggests that although the sumoylated and ADP-
ribosylated lysines are rather close within the PARP1
amino acid sequence, their modifications do not
interfere with each other.
Sumoylation counteracts p300-induced acetylation of
PARP1
As p300 is critical for PARP1 transcriptional coactiva-
tion and acetylates PARP1 at distinct lysines (6), we first
examined whether acetylated PARP1 would still be
sumoylated in vitro. Acetylation of PARP1 was moni-
tored with a specific anti-acetyl PARP1 (E4) antibody
(Supplemental Fig. 5A), while sumoylation was assessed
by the migration difference between unmodified
PARP1 and Su-PARP1. Acetylation with the indicated
control and subsequent addition of sumoylation en-
zymes, followed by the sumoylation reaction, revealed
that similar to the mono-ADP-ribosylated PARP1, acety-
lated PARP1 could also be efficiently modified with
SUMO (Fig. 4A, lane 4).
Moreover, we tested whether sumoylation of PARP1
would affect acetylation. Purified Su-PARP1 or de-
sumoylated PARP1 by recombinant SENP2 was both
incubated with p300 and acetyl-CoA in vitro. Western
blot analysis using the specific anti-acetyl PARP1 (E4)
antibody revealed that PARP1 is acetylated only when
PARP1 was desumoylated prior to acetylation (Fig. 4B,
lane 2), suggesting that the SUMO-modification inhib-
its p300-mediated PARP1 acetylation. To substantiate
this, we examined protein interactions with p300,
PARP1, or Su-PARP1. p300 could interact efficiently
with PARP1 but not with Su-PARP1, as demonstrated by
coimmunoprecipitation of p300 (Fig. 4C). Thus, the
absence of detectable acetylation of Su-PARP1 (see Fig.
4B) suggests that SUMO modification at K486 prevents
p300-mediated acetylation of PARP1, likely because of
steric hindrance of the bulky SUMO conjugate block-
ing p300 binding and acetylation at the adjacent lysine
residues. To explore whether the inhibitory effect of
PARP1 sumoylation on acetylation is also observed in
vivo, we coexpressed wild-type PARP1 or the sumoyla-
tion-deficient PARP1 mutant (K486R) with p300 and
monitored acetylation with the E4 antibody on Western
blots. This revealed lower levels of acetylation for the
wild-type PARP1 compared to the sumoylation-defi-
Figure 4. Sumoylation counteracts p300-induced acetylation of PARP1. A) In vitro
acetylation of PARP1 through p300 was done in the absence (lanes 1 and 3) or the
presence (lanes 2 and 4) of acetyl-CoA. Proteins necessary for sumoylation (E1,
E2, SUMO3) were added after the acetylation reaction. Proteins were separated
with SDS-PAGE and analyzed with anti-PARP1 and anti-acetyl-PARP1 (E4) anti-
body. B) In vitro acetylation reaction was done with p300 and sumoylated PARP1
(lane 1) or PARP1 desumoylated prior to the acetylation reaction (lane 2). After
acetylation reaction, sumoylated PARP1 was desumoylated with SENP2 (lane 1),
which allowed direct comparison of acetylation status of equal amounts of PARP1.
C) Coimmunoprecipitation of p300 with PARP1 was carried out on protein G
sepharose beads, using HA antibody to capture HA-tagged PARP1, either sumoy-
lated (Su-PARP1) or desumoylated (deSu-PARP1). As control, only the HA
antibody was bound to the matrix (no PARP1). Beads were incubated with purified p300, and the unbound fraction was
removed by extensive washing. D) HEK293T cells were transfected with either HA-PARP1 wt or HA-PARP1 K486R mutant
along with p300 expression plasmid. Cells were incubated with HDAC inhibitors 2 h prior to lysis, and HDAC inhibitors
were present at all steps of manipulation. Nuclear extracts were taken and subjected to immunoprecipitation using an HA
antibody. After SDS-PAGE, proteins were detected by anti-acetyl-PARP1 (E4), anti-HA, or anti-p300 antibody.
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cient PARP1 mutant (Fig. 4D). Together, these results
provide evidence for a crosstalk between these modifi-
cations.
The sumoylation-deficient K486R PARP1 mutant
exhibits higher coactivator function compared to
wild-type PARP1
To explore a possible mechanism by which sumoyla-
tion affects PARP1-dependent transcriptional coacti-
vator function in vivo, we first knocked down endog-
enous PARP1 protein levels in K562 cells with an
shRNA approach directed against the untranslated
region of PARP1’s mRNA and subsequently comple-
mented these cells with wild-type or sumoylation-
deficient K486R PARP1 mutant (Fig. 5A, B). The
expression levels of the complemented cells were
comparable to the endogenous wild-type counter-
part. Hypoxia treatment of these cells for 28 h and
subsequent profiling of the gene expression of de-
fined hypoxia-inducible genes revealed that certain
genes, such as CAIX, LOXL2 or Pdk1, are dependent
on PARP1, but only a subset was affected by the
sumoylation-deficient K486R mutation (Fig. 5C).
Similar results were obtained when PARP1/ mouse
lung fibroblasts were complemented with wild-type
or sumoylation-deficient K486R PARP1 mutant and
stimulated by the hypoxia-mimicking drug ciclopir-
oxolamine (Supplemental Fig. 5B). Sumoylation-de-
ficient K486R PARP1 mutant not only enhanced
CAIX mRNA levels in K562 cells, but also CAIX
protein levels in vivo (Fig. 5D). Furthermore, hypoxia
treatment of K562 cells very strongly correlated with
protein sumoylation and enhanced SUMO modifica-
tion of PARP1 in HEK293T cells (Supplemental Fig.
5C, D). Thus, we conclude that sumoylation of PARP1
reduces its coactivator activity and thus regulates
gene expression in vivo.
Figure 5. Sumoylation-deficient K486R PARP1 mutant ex-
hibits higher coactivator function compared to wild-type
PARP1. A) Stable knockdown of PARP1 in human chronic
myelogenous leukemia cell line K562 using a lentiviral
system. shRNA against PARP1 targets the 5 untranslated
region of PARP1 mRNA. B) Stable complementation of
PARP1 with either pRRL-empty vector, myc-tagged wild-
type PARP1, and sumoylation-deficient PARP1 K486R mu-
tant. C) Hypoxic induction of complemented K562 cells at
0.2% O2 for 28 h. RNA was isolated, and the quantitative
PCR was done using primers for carbonic anhydrase IX
(CAIX), lysyl oxidase-like 2 (LOXL2), and pyruvate dehy-
drogenase kinase, isenzyme 1 (Pdk1) and normalized by
using L28 ribosomal protein. Normoxic samples were set to
1; fold induction of hypoxic samples is depicted. Three
biological replicates are shown. Statistical analysis was done with unpaired t test between biological replicates. Data are
represented as means 	 se. D) Complemented K562 cells were exposed for 29 h to 0.2% O2 hypoxia. Whole-cell extracts
were prepared and Western blotted with monoclonal anti-CAIX antibody and anti-tubulin antibody.
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DISCUSSION
The aim of this study was to characterize and investigate
the role of PARP1 sumoylation in the cellular context.
We provide biochemical and cellular evidence for
SUMO modification of PARP at lysine 486 within its
automodification domain. Mutation of K486 enhances
the transcriptional activity of PARP1, suggesting that
sumoylation restrains its transcriptional activity.
PARP1 is covalently sumoylated
Noncovalent interactions of proteins can occur
through SUMO interaction motifs (SIMs) (27). Pro-
teins like the DNA repair enzyme TDG and the tumor
suppressor PML were shown to interact with SUMOs
via SIMs, and such interactions were associated with
important biological activities (28 –30). Although
PARP1 exhibits several putative SIMs, we did not
observe any direct noncovalent interaction of PARP1
with SUMOs, indicating that the interaction of
PARP1 with SUMO is exclusively covalent. Pulldown
experiments of sumoylated PARP1 under denaturat-
ing conditions and site-directed mutagenesis re-
vealed that sumoylation of PARP1 is indeed a cova-
lent and site-specific modification. A possible in-
volvement of SUMO E3 ligases for the sumoylation of
PARP1 needs further investigations. Although PIAS
family members are attractive candidates, overex-
pression of different PIAS proteins did not enhance
PARP1 sumoylation (data not shown).
Notably, we observed only monosumoylation of
PARP1 in vivo, but do not exclude that under specific
conditions, PARP1 may also be polysumoylated. In
support of this idea, heat shock has been reported to
induce a pattern of PARP1 sumoylation, which would
be consistent with polysumoylation (18). Understand-
ing the balance between monosumoylation and poly-
sumoylation of PARP1, as well as their functional
differences will remain an exciting issue.
Crosstalk between sumoylation and other
post-translational modifications
The crosstalk of post-translational modification systems
is an emerging concept (31). Sumoylation of target
proteins can be regulated through crosstalks with other
post-translational modification events. Phosphoryla-
tion, for instance, was shown to regulate SUMO conju-
gation through a highly conserved motif, which is
called phosphorylation-dependent sumoylation motif
(PDSM) (32). The PDSM motif, which contains a
SUMO consensus site and an adjacent proline-directed
phosphorylation site (KxExxSP, where  represents
large hydrophobic residue and x is any amino acid),
regulates phosphorylation-dependent sumoylation of
multiple transcription factors (33–35). Lysine residues
are targeted by several other post-translational modifi-
cations, including ubiquitination, acetylation, methyl-
ation, and ADP-ribosylation. It has been documented
that SUMO conjugation can occur on the same lysine
residue as ubiquitination or acetylation in some pro-
teins. For example, the competition between sumoyla-
tion and ubiquitination of the same lysine regulates the
stability of I
B (36), whereas in other cases, sumoyla-
tion acts as a recognition signal for a ubiquitin ligase
(37). An interplay between sumoylation and acetylation
has been observed in the regulation of proteins, such as
MEF2, the core histones, and hypermethylation in
cancer 1 (HIC1) (38, 39). In the case of MEF2, the
sumoylation-acetylation switch is regulated by phos-
phorylation (40). These studies demonstrate the impor-
tance of signaling crosstalk in the regulation of protein
sumoylation.
Mechanisms of SUMO-mediated repression of PARP1
coactivator function
First, sumoylation may directly affect PARP1’s binding
to DNA by promoting its dissociation from specific
chromatin regions. This possibility seems unlikely,
since sumoylation of PARP1 did not alter its ability to
recognize and bind damaged DNA in vitro. Second,
SUMO modification could also affect enzymatic activi-
ties of PARP1, which is important for gene expression.
Also, this seems unlikely, since we have shown that
SUMO modification of PARP1 does not interfere with
DNA-dependent ADP-ribosylation activity in vitro. In
addition, increased SUMO3 levels do not correspond to
elevated poly(ADP-ribosyl)ation in cells on hydrogen
peroxide-induced DNA damage, suggesting that sumoy-
lation of PARP1 does not have a stimulatory effect on its
enzymatic activity. However, it was shown that poly-
(ADP-ribosyl)ation is not required for NF-
B-depen-
dent gene expression (41). Neither the enzymatic
activity of PARP1 nor its binding to DNA was required
for full activation of NF-
B in response to various
stimuli in vivo when tested on transiently transfected
reporter plasmids (21, 42). Consistently, the enzymatic
activity of PARP1 was not required for full transcrip-
tional activation of NF-
B in the presence of the
histone acetyltransferase p300 (6). Because sumoyla-
tion of PARP1 inhibits its acetylation at adjacent lysine
residues and because these residues are also targets of
ADP-ribosylation, a potential acetylation-ADP-ribosyla-
tion switch, which is controlled through sumoylation of
PARP1, is very likely. Third, the SUMO modification
could promote or inhibit protein-protein interactions
through protein complex formation. This scenario
seems to be the most relevant for PARP1, since the
interaction of PARP1 with p300 and subsequent PARP1
acetylation was impaired after sumoylation of PARP1 at
K486. This lysine residue lies within the domain of
PARP1, which contributes to most protein-protein in-
teractions such as XRCC1 (6). However, we did not
observe a general SUMO-dependent inhibition of pro-
tein interactions in this region since HIF1- and
XRCC1 binding does not seem to be affected by
sumoylation of PARP1 (Supplemental Fig. 5E and un-
published results). In addition to the inhibition of p300
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binding, SUMO modification of PARP1 may facilitate
the recruitment of a transcriptional corepressor. Cur-
rently, several chromatin-modifying enzymes and chro-
matin-binding proteins have been implicated as effec-
tors of SUMO-mediated repression. For example,
SUMO modification of the transcription factor Elk-1
promotes recruitment of HDAC2, associated with his-
tone deacetylation and transcriptional repression of the
c-fos promoter (43). Very recently, CoREST1 and Mi2
were identified as SUMO-dependent corepressors, and
evidence was provided that CoREST1 binds directly and
noncovalently to SUMO2/3, but not to SUMO1 (44,
45). Notably, the aforementioned interaction of PARP1
with PIAS family members could contribute to gene
silencing.
Desumoylation of PARP1 by SENP1 and SENP3
We observed that SENP1 and SENP3 are able to
catalyze PARP1’s SUMO deconjugation. The nucleo-
plasmic SENP1 relieves SUMO-dependent repression
of Ets1, c-Jun, and the androgen receptor, the latter
effect being through desumoylation of histone deacety-
lase 1 (46). Recent data also implicate the nucleolus in
dynamic cycles of sumoylation and desumoylation. For
example, nucleolar SENP3 is able to catalyze desumoy-
lation of various proteins in this compartment, with
specificity to SUMO2/3 (15, 46). In addition, it seems
that SENPs regulate SUMO paralog preference of
substrate proteins by deconjugation of specific SUMOs,
as shown for RanGAP1 (47). This could also explain the
higher steady-state level of SUMO3-modified than
SUMO1-modified PARP1.
Only a subset of PARP1-dependent genes are
affected by sumoylation
Analyses of the role of SUMO in transcriptional regu-
lation have mainly relied on the use of protein overex-
pession and transiently transfected reporter genes,
which may not give a true reflection of the physiological
situation. Therefore, we have established a system
where we complement cells depleted from endogenous
PARP1 with sumoylation deficient PARP1 or wild-type
PARP1 and analyzed the expression of endogenous
target genes. Known HIF1- dependent genes with a
high induction upon hypoxia were tested. Of these,
CAIX and LOXL2 showed increased transcript levels in
sumoylation deficient K486R mutant cell line, whereas
other genes were solely dependent on PARP1, but not
on its sumoylation. Consistent with the qPCR data, the
expression levels of CAIX were increased in cells ex-
pressing sumoylation-deficient PARP1. Previous studies
on PARP1’s coactivator function revealed that this
function is heavily dependent on its acetylation
through p300. Here, we showed that acetylation is
abrogated if the SUMO moiety is present on PARP1.
Consistently, the sumoylation-deficient mutant showed
a higher acetylation status, which corresponded to
higher gene expression status for some genes. Collec-
tively, these data support the mechanistic studies per-
formed in vitro, unraveling an important role of sumoy-
lation in regulating PARP1-dependent transcriptional
coactivation through regulation of its acetylation. It is
largely accepted that post-translational modifications
fine tune and regulate the requirement of certain
transcriptional cofactors for gene expression by tran-
scription factors and might thus influence only a subset
of genes (48).
Hypoxia-induced gene expression is affected by
PARP1 sumoylation
The role of sumoylation in the regulation of hypoxia-
induced gene expression and HIF-1 stability is
controversial (49). Hypoxia can induce the expres-
sion of SUMO1 (50) and an RWD-containing sumoy-
lation enhancer (RSUME) that functions as a promoter
of protein sumoylation (51). RSUME expression is in-
duced by hypoxia, which leads to the enhanced
sumoylation and stabilization of HIF-1. Alterna-
tively, a recent study indicates that the hypoxia-
induced sumoylation of HIF-1 targets HIF-1 for
degradation through the von Hippel–Lindau (VHL)
protein-mediated ubiquitin-proteasome pathway
(37). Clearly, further studies are needed to clarify
these controversial findings on the role of sumoyla-
tion in the regulation of HIF-1 stability during
hypoxia. In this study, we have investigated the
regulation of the known HIF1--dependent genes
CAIX and LOXL2 and provide novel insights to
understand the complex transcriptional regulation
of these emerging tumor markers. The expression of
these genes is restrained through SUMO modifica-
tion of the transcriptional coactivator PARP1, indi-
cating that sumoylation of PARP1 dampens HIF1-
signaling for these genes. Thus, this pathway may
have an important regulatory role in the regulation
of intracellular pH and hypoxia-induced metastasis
(52, 53). Moreover, it remains to be elucidated
whether sumoylation of PARP1 is also affecting tran-
scription mediated by other transcription factors and
whether SUMO modification is associated with the
role of PARP1 in several pathophysiological disease
models. Further studies of the sumoylation of PARP1
will determine the role of SUMO modification/
deconjugation in these pathological states.
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